CeGaT participates in pancreatic cancer research

CeGaT GmbH has joined a scientific research consortium of leading European scientists to identify the genetic causes of pancreatic cancer. The European Union FP7-Programm, which will last five years, is publicly funded with over 11 million euros. Eleven partners from five countries are working together for a better understanding of this extremely aggressive and difficult-to-treat cancer. Prof. Dr. Thomas Gress, University hospital Marburg, and PD Dr. Malte Buchholz, University of Marburg, have initiated and are coordinating the joint efforts of physicians, molecular biologists, computer specialists, and small to medium companies.

The central goal of CAM-PaC is the development of pancreatic cancer computer models that will be used to identify new therapeutic targets and molecules. CeGaT is contributing to the consortium by providing its expertise in transcriptomic profiling and interpretation. The first step is the establishment of routine protocols for quantitative interpretation of transcriptomes of clonal-sphere-cultures (CSC) that assemble approximately 40 – 100 individual cells. For interpretation of the obtained results, CeGaT will closely interact and develop new algorithms together with the group of PD Dr. Hans Kestler, University of Ulm.

CeGaT celebrates roofing ceremony

Seven months after the ground-breaking ceremony CeGaT celebrated yesterday afternoon the roofing ceremony of the new CeGaT office and laboratory building.

View more “About CeGaT“.

 

GenomeWeb interview with Saskia Biskup

Today GenomeWeb published a long interview with Saskia Biskup. Saskia talks about CeGaT’s Diagnostic Panels and its significant advantages over single gene testing. She also presents the Tumor pipeline recently introduced by CeGaT. Furthermore Saskia announced the launch of an extensive Pharmacogenomics (PGx) Panel with more than 340 genes.

The complete interview can be read on the GenomeWeb website